Navigation Links
GenturaDx Appoints Senior Vice President of Research & Development
Date:7/11/2011

HAYWARD, Calif., July 11, 2011 /PRNewswire/ -- Molecular diagnostics company GenturaDx announced today that Geoffrey A. McKinley, Ph.D., has joined the company as Senior Vice President of Research & Development.  McKinley joins as GenturaDx accelerates research to bring its IDbox™ System to commercialization.

(Photo:  http://photos.prnewswire.com/prnh/20110711/LA32940)

"With his depth of experience developing molecular diagnostic products, Geoff will be a key asset in commercializing our molecular platform in the next 12 to 24 months," said Mark Bagnall, GenturaDx's chief executive officer. "GenturaDx anticipates completing beta studies this year and clinical studies in 2012, and Geoff is an important addition to a talented R & D team working to perfect our system as well as develop partnerships with companies that seek to adapt assay content to our platform."

Dr. McKinley brings to GenturaDx nearly two decades of research & development and business development experience related to developing molecular diagnostic products and tools for infectious diseases.  Prior to joining GenturaDx, Dr. McKinley was responsible for research & development to support molecular biology assay, consumable and instrumentation development at Osmetech, Inc. He has previously held positions at Naxcor, Inc., BioMerieux, Inc., and Analytab Products, a division of Sherwood Medical. Dr. McKinley earned his Ph.D. at Colorado State University.

"It's a great time to be at GenturaDx," Dr. McKinley said, "because its unique, PCR-based, sample-to-answer IDbox System has the potential to dramatically impact molecular diagnostics, offering potential performance advantages over existing systems on the market and making the molecular testing affordable and easy to use for the estimated 5,000 small-to-medium sized hospitals that rely on traditional culture techniques or immunoassay testing."

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making molecular diagnostics both affordable and practical for any laboratory to perform.  The company's IDbox System incorporates all aspects of proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform reduces the risk of contamination and saves time; the platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test.


'/>"/>
SOURCE GenturaDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Appoints New Chief Medical Officer
2. West Pharmaceutical Services, Inc. Appoints New Director
3. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
4. Curemark Appoints Preeminent Pediatrics Gastroenterologist
5. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. NovaRx Appoints Industry Veteran as President and COO
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ), ... services to office-based dental, animal health and medical practitioners, ... to acquire a majority ownership interest in Dental Cremer ... Brazil . ... Cremer is the dental distribution business of Cremer S.A. ...
Breaking Medicine Technology:
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/7/2016)... ... 07, 2016 , ... Women's Excellence staff, in all four locations, wore red ... Red Day is the first Friday each February and a day to bring attention ... 3 deaths among women each year – more than all cancers combined. Go Red ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
(Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
Breaking Medicine News(10 mins):